Close
Project Summary
In recent years, several biomarkers have been consistently demonstrated as indicative of immune competence/function in different cohorts of patients affected by the afore-mentioned chronic conditions. And yet, despite intense research to prove the association between biomarkers and
disease outcome, few have gone through all the process of clinical validation, therefore still remaining distant from clinical use.
Progressing such biomarkers towards clinical validation is a crucial step in reaching the finest monitoring of disease progression and treatment response in chronic clinical settings. By allowing the earliest detection of patients with an increased clinical risk, such a biomarker-based approach will help the progress towards “precision” clinical strategies in these patients.
Key Project Information
Dates: 1st February 2025 - 21st January 2028
UCL lead/Principal Investigator: Professor Alessandro Cozzi-Lepri
Lead organisation: Institute for Global Health, UCL
Project lead: EuResist Network GEIE
Partners: A. Menarini Diagnostics, Altona Diagnostics GmbH, , Azienda Socio-Sanitaria Territoriale – ASST Santi Paolo e Carlo, Diatheva SRL, European Aids Treatment Group EV, European Liver Patients’ Association, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, HHU, Karolinska Institute, mib Dienstleistung GmbH, PEI, Qiagen GmbH, Roboscreen GmbH, SIAL, Universitätsklinikum Köln, University of Rome Tor Vergata, University of Siena
Location: Belgium, Germany, Italy and Sweden
Funding: EC Horizon Europe
Contact: a.cozzi-lepri@ucl.ac.uk
- Research Team
Bjoern-Erik Ole Jensen
Anders Sonnerborg
Maurizio Zazzi
Francesca Ceccherini Silberstein
Pietro Lampertico
Giulia Marchetti
Nicoletta Policek